• Oxbridge Re entered an at-the-market sales agreement with Chardan Capital Markets to sell ordinary shares from time to time.
• Program size capped at an aggregate offering price of up to $1.68 million under an existing Form S-3 shelf registration statement.
• Chardan to receive a 3% commission on gross proceeds; legal fee reimbursement capped at $20,000.
• Net proceeds earmarked for general corporate purposes, including funding reinsurance operations.
• Agreement replaces a prior at-the-market sales agreement with Maxim Group that was terminated on June 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oxbridge Re Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029634), on June 22, 2026, and is solely responsible for the information contained therein.